Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 531146 | NSE Symbol : MEDICAMEQ | ISIN : INE646B01010 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
24-Apr-2025	24-Apr-2025	Preferential Issue	We wish to inform you that the Board of Directors of the Company at their meeting held today i.e Thursday, April 24, 2025 has inter alia considered and approved the following : 1. Allotment of 8,48,220 Equity Shares 2.Allotment of 6,50,000 fully convertible warrants Revised outcome of Board Meeting - 24.04.2025 (As Per BSE Announcement Dated on: 25/04/2025)
21-Feb-2025	26-Feb-2025	Preferential Issue	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/02/2025 inter alia to consider and approve We wish to inform you that a meeting of the Board of Directors is scheduled to be held on Wednesday February 26 2025 inter alia to consider and approve a proposal for raising of funds by way of issuance of one or more instruments including equity shares/convertible securities either by way of Preferential Issue/Right Issue/QIP or any other mode. Announcement under Regulation 30 (LODR)- Issue of Securities (As Per BSE Announcement Dated on: 26/02/2025)
04-Feb-2025	11-Feb-2025	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve the standalone and consolidated unaudited financial results of the company for the quarter ended on Decmeber 31 2024. Appointment of Mr. Chandan Kumar as Chief Financial Officer and Key Managerial Personnel of the Company w.e.f February 11, 2025 Outcome of Board meeting held on 11.02.2025 (As per BSE Announcement Dated on 11/02/2025)
07-Nov-2024	14-Nov-2024	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30 2024. Outcome of the Board Meeting held on 14-11-2024 (As Per BSE Announcement dated on 14.11.2024)
07-Aug-2024	13-Aug-2024	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Un-audited Financial Results (Standalone & Consolidated) for the quarter ended on June 30 2024 and for draft Annual Report for the FY 2023-24 Financial Results for the quarter ended on 30.06.2024 (As per BSE Announcement Dated on 13/08/2024)
21-May-2024	29-May-2024	Final Dividend	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Audited Financial Results (Standalone & Consolidated) for the quarter & year ended on 31.03.2024 and to approve Final Dividend for the FY 2023-24. Approval of Audited Financial Results for the quarter ended on 31.03.2024 and recommendation of Final Dividend for the FY 2023-24 (As Per BSE Announcement Dated on 29/05/2024)
13-Feb-2024	13-Feb-2024	Conversion	In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good office that the Board of Directors of the Company, Medicamen Biotech Limited, at their meeting held today i.e February 13, 2024 at 05.00 PM has, inter alia, considered and approved the allotment of 63,500 Equity Shares of face value of Rs. 10/- each pursuant to conversion of 63,500 Fully Convertible Warrants ('Warrants') issued as on September 12, 2022, at an issue price of Rs. 709/- each, by way of preferential allotment.
05-Feb-2024	12-Feb-2024	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter and nine months ended on December 31 2023. Unaudited Financial Results for the Quarter and Nine months ended on December 31, 2023 (As Per BSE Announcement Dated on: 12/02/2024)
02-Nov-2023	10-Nov-2023	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve the Unaudited Financial Results for the Quarter and Half Year ended on September 30 2023. Un-audited Financial Results- Quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 10.11.2023)
01-Aug-2023	08-Aug-2023	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve Medicamen Biotech Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended June 30 2023 This is to inform you that the Board of Directors of the Company in its meeting held today i.e August 08, 2023, which commenced at 12.30 pm and concluded at 02.15 pm inter alia considered and approved the unaudited financial results of the company for the quarter ended on June 30, 2023. Outcome of the Board Meeting held on August 08, 2023 (As Per BSE Announcement dated on 08.08.2023)
22-May-2023	29-May-2023	Accounts	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve We wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited (the Company) is scheduled to be held on Monday May 29 2023 at the registered office of the Company situated at 1506 Chiranjiv Tower 43 Nehru Place New Delhi-110019 to inter-alia consider and approve the following business(s): 1. The Audited Financial Results of the Company (Standalone and Consolidated) for the quarter / year ended on March 31 2023 2. To consider the recommendation of Final Dividend on Equity Shares of the Company for the financial year 2022-23 Any other business with the permission of the chair This is for your information and record. We wish to inform that the Board of Directors of the Company in its meeting held today i.e. May 29, 2023, which commenced at 02.30 p.m. and concluded at 04.00 p.m., inter alia, considered and approved the Audited Standalone & Consolidated Financial Results of the Company for year ended March 31, 2023 , further details attached. (As Per BSE Announcement dated on 29.05.2023)
31-Jan-2023	10-Feb-2023	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited (the Company) is scheduled to be held on Friday February 10 2023 at the registered office of the Company situated at 1506 Chiranjiv Tower 43 Nehru Place New Delhi-110019 to inter-alia consider and approve the following business(s): 1. The Un-audited Financial Results of the Company (Standalone and Consolidated) along with the Limited Review Report (Standalone & Consolidated) for the quarter and nine months ended on December 31 2022. 2. Any other business with the permission of the chair. This is for your information and record. Financial Results For The Quarter And Nine Months Period Ended On 31st December 2022. We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended on December 31, 2022. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following: a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2022 as Annexure-A and b) Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as Annexure-B c) An Investor Presentation of the company is enclosed as Annexure-C The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.30 p.m. (As Per BSE Announcement dated on 10.02.2023)
04-Nov-2022	11-Nov-2022	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited (the Company) is scheduled to be held on Friday November 11 2022 at the registered office of the Company situated at 1506 Chiranjiv Tower 43 Nehru Place New Delhi-110019 to inter-alia consider and approve the following business(s): 1. The Un-audited Financial Results of the Company (Standalone and Consolidated) for the quarter and half year ended on September 30 2022. 2. Any other business with the permission of the chair. This is for your information and record. We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended on September 30, 2022. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following: a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2022 as Annexure-A and b) Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as Annexure-B c) An Investor release on the financial results is enclosed as Annexure-C The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.30 p.m. (As Per BSE Announcement dated on 11.11.2022) Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ('the Regulations'), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2022 approved by the Board of Directors at their Meeting held on 11.11.2022. The copy of the results published in the Financial Express and Jansatta dated November 12, 2022 is enclosed. This is for your information and records. Kindly acknowledge the receipt. (As per BSE Announcement Dated on 15/11/2022)
12-Sep-2022	12-Sep-2022	Preferential Issue	In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations, 2015'), we wish to inform your good office that the Board of Directors of the Company, at their meeting held today i.e., September 12, 2022 at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019, has, inter alia, considered and approved the following businesses: 1. Allotment of 4,34,500 Equity Share for cash at an issue price of Rs. 709/- per Equity Share by way of preferential allotment 2. Allotment of 63,500 Fully Convertible Warrants ('Warrants') each carrying a right to subscribe to one Equity Share per Warrant, for cash at an issue price of Rs. 709/- per warrant by way of preferential allotment
03-Aug-2022	10-Aug-2022	Quarterly Results	MEDICAMEN BIOTECH LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that a Meeting of the Board of Directors of Medicamen Biotech Limited (the Company) is scheduled to be held on Wednesday August 10 2022 at the registered office of the Company situated at 1506 Chiranjiv Tower 43 Nehru Place New Delhi-110019 to inter-alia consider and approve the following business(s): 1. The Un-audited Financial Results of the Company (Standalone and Consolidated) for the quarter ended on June 30 2022. 2. To consider & approve draft Annual Report for the financial year 2021-22 3. Any other business with the permission of the chair. This is to inform that the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022 were approved by the Board of Directors of the Company at its meeting held today i.e. August 10, 2022. Further details attached. (As Per BSE Announcement dated on 10.08.2022)

1 2

LOGIN HERE

Medicamen Biotech Ltd

Board Meeting